Optimi Health (OPTH) has upcoming FDA regulatory milestones for psilocybin-assisted therapy. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Optimi Health (OPTH).
Over the past two years, Optimi Health has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
OPTI-201 and psilocybin-assisted. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
OPTI-201 FDA Regulatory Events
OPTI-201 is a drug developed by Optimi Health for the following indication: in Major Depressive Disorder.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- OPTI-201
- Announced Date:
- November 18, 2026
- Indication:
- in Major Depressive Disorder
Announcement
Optimi Health Corp provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement.
Read Announcement
Psilocybin-assisted therapy FDA Regulatory Timeline and Events
Psilocybin-assisted therapy is a drug developed by Optimi Health for the following indication: for Major Depressive Disorder.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- psilocybin-assisted therapy
- Announced Date:
- September 10, 2026
- Target Action Date:
- H1 2027
- Estimated Target Date Range:
- January 1, 2027 - June 30, 2027
- Indication:
- for Major Depressive Disorder
Announcement
Optimi Health Corp announced that the trial is planned to be initiated in the first half of 2027
AI Summary
Optimi Health Corp. announced that it completed and released for quality a production batch of 5 mg naturally derived psilocybin capsules. The capsules were manufactured from start to finish at the company’s cGMP facility in Princeton, British Columbia, which operates under a Health Canada Drug Establishment Licence.
The batch supports Optimi’s plans to supply its own psilocybin for a Health Canada-authorized Phase 2 trial of psilocybin-assisted therapy for major depressive disorder. The study is planned to begin in the first half of 2027 and enroll up to 200 people at sites across Canada. It will examine the safety and effectiveness of one supervised dose, with dosing expected to finish by the end of 2027. Researchers will track changes in depression symptoms using a standard clinical rating scale. Optimi says the study will include interim updates and that full results will follow after participants complete dosing and follow-up. Psilocybin-assisted therapy remains under investigation, and Optimi’s products are not approved for sale by Health Canada.
Read Announcement- Drug:
- psilocybin-assisted therapy
- Announced Date:
- September 10, 2026
- Target Action Date:
- LATE 2027
- Estimated Target Date Range:
- October 1, 2027 - December 31, 2027
- Indication:
- for Major Depressive Disorder
Announcement
Optimi Health Corp. announced that the dosing expected to be complete by the end of 2027.
AI Summary
Optimi Health Corp. announced that it completed and released for quality a production batch of 5 mg naturally derived psilocybin capsules. The capsules were manufactured from start to finish at the company’s cGMP facility in Princeton, British Columbia, which operates under a Health Canada Drug Establishment Licence.
The batch supports Optimi’s plans to supply its own psilocybin for a Health Canada-authorized Phase 2 trial of psilocybin-assisted therapy for major depressive disorder. The study is planned to begin in the first half of 2027 and enroll up to 200 people at sites across Canada. It will examine the safety and effectiveness of one supervised dose, with dosing expected to finish by the end of 2027. Researchers will track changes in depression symptoms using a standard clinical rating scale. Optimi says the study will include interim updates and that full results will follow after participants complete dosing and follow-up. Psilocybin-assisted therapy remains under investigation, and Optimi’s products are not approved for sale by Health Canada.
Read Announcement- Drug:
- psilocybin-assisted therapy
- Announced Date:
- September 10, 2026
- Indication:
- for Major Depressive Disorder
Announcement
Optimi Health Corp announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder ("MDD").
AI Summary
Optimi Health Corp. announced that it completed and released for quality a production batch of 5 mg naturally derived psilocybin capsules. The capsules were manufactured from start to finish at the company’s cGMP facility in Princeton, British Columbia, which operates under a Health Canada Drug Establishment Licence.
The batch supports Optimi’s plans to supply its own psilocybin for a Health Canada-authorized Phase 2 trial of psilocybin-assisted therapy for major depressive disorder. The study is planned to begin in the first half of 2027 and enroll up to 200 people at sites across Canada. It will examine the safety and effectiveness of one supervised dose, with dosing expected to finish by the end of 2027. Researchers will track changes in depression symptoms using a standard clinical rating scale. Optimi says the study will include interim updates and that full results will follow after participants complete dosing and follow-up. Psilocybin-assisted therapy remains under investigation, and Optimi’s products are not approved for sale by Health Canada.
Read Announcement